Loading...
Docoh
Log in Free sign up

Centrexion Therapeutics (CNTX)

Company profile

Ticker
CNTX
Exchange
NASDAQ
Employees
Incorporated
Delaware
Location
Massachusetts
Fiscal year end
Dec 31
Sector
Health Technology > Biotechnology
Industry (SIC)
Pharmaceutical Preparations
Pfizer • Johnson & Johnson • Merck & Co • Allergan • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie ...
Former names
Centrexion Corp
SEC CIK
0001592052
Corporate docs
IRS number
320402377

News

From Benzinga Pro
Context Therapeutics Q1 EPS $(0.22) Up From $(2.55) YoY
11 May 22
Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.22) per share. This is a 91.37 percent increase over losses of $(2.55) per share from the same period last year.
Stocks That Hit 52-Week Lows On Thursday
28 Apr 22
During Thursday, 849 stocks hit new 52-week lows.
Stocks That Hit 52-Week Lows On Wednesday
27 Apr 22
Wednesday's session saw 784 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Thursday
21 Apr 22
Context Therapeutics To Present Data From Two Programs At AACR Apr. 13
11 Apr 22

Press releases

From Benzinga Pro
Context Therapeutics® Reports First Quarter 2022 Operating and Financial Results
11 May 22
Abstract on results of the monotherapy portion of Phase 2 ONA-XR clinical trial in granulosa cell tumors of the ovary accepted for oral presentation at the 2022 ASCO Annual Meeting Preclinical data presented at AACR
Context Therapeutics® Announces Encouraging Preclinical Data from Two Programs to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2022
11 Apr 22
Lead clinical-stage oral progesterone receptor (PR) antagonist ONA-XR demonstrates strong efficacy across multiple PR+ solid tumor models First presentation of preclinical CLDN6xCD3 bispecific antibody optimization,
Context Therapeutics® to Participate in Two April 2022 Investor Conferences
6 Apr 22
PHILADELPHIA, April 06, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a women's oncology company developing small molecule and immunotherapy treatments for breast and
Context Therapeutics® Reports Full Year 2021 Operating and Financial Results
23 Mar 22
Context Therapeutics® Announces Acceptance of Five Abstracts to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2022
8 Mar 22

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

17 May 22
31 Dec 22
Financial reports
No filings
Current reports
No filings
Registration and prospectus
View all
RW
Registration withdrawal request
5 May 21
D
$13.5M in debt / securities to be acquired, sold $13.5M, 17 investors
26 Jan 21
S-1/A
IPO registration (amended)
23 Dec 19
S-1/A
IPO registration (amended)
18 Sep 19
S-1/A
IPO registration (amended)
9 Nov 18
S-1/A
IPO registration (amended)
5 Nov 18
8-A12B
Registration of securities on exchange
5 Nov 18
S-1
IPO registration
19 Oct 18
DRS/A
Draft registration statement (amended)
16 Oct 18
DRS
Draft registration statement
9 Sep 18
Proxies
No filings
Other
CERT
Certification of approval for exchange listing
13 Nov 18

Patents

View all
Utility
(4-((3R,4R)-3-METHOXYTETRAHYDRO-PYRAN-4-YLAMINO)PIPERIDIN-1-YL)(5-METHYL-6-(((2R,6S)-6-(P-TOLYL)TETRAHYDRO-2H-PYRAN-2-YL)METHYLAMINO)PYRIMIDIN-4-YL)METHANONE Citrate
5 May 22
The invention provides a salt of a tetrahydropyranylmethylaminopyrimidine amide, such as the citrate salt of (4-((3R,4R)-3-methoxytetrahydropyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4-yl)methanone, pharmaceutical compositions containing the same, processes for preparing the same, and methods of medical treatment using the same.
Utility
Novel (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]THIADIAZOLES
5 May 22
This invention relates to novel (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles and their use as CB2 cannabinoid receptor agonists, pharmaceutical compositions containing the same, and their use for the treatment of CB2 receptor mediated disorders or conditions.
Utility
Capsaicinoid prodrug compounds and their use in treating medical conditions
22 Feb 22
The invention provides capsaicinoid prodrug compounds (e.g., prodrugs of resiniferatoxin, tinyatoxin, iodoresiniferatoxin, and related compounds), pharmaceutical compositions, and their use in the treatment of medical conditions, such as pain, and in agonizing TRPV1 activity.
Utility
CCR2 Receptor Antagonists and Uses Thereof
6 Jan 22
The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.
Utility
Compositions and Methods for Intrathecal Administration of Mcoppb for Pain Relief
16 Dec 21
The invention provides compositions and methods for intrathecal administration of the compound MCOPPB or a pharmaceutically acceptable salt thereof for treating pain, such as neuropathic pain suffered by an adult human.

Reddit threads

View all